Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cone-rod dystrophy in which the cause of the disease is a mutation in the POC1B gene.
Features include always present findings: Constriction of peripheral visual field, Nystagmus, Reduced visual acuity, and Central scotoma; and common findings: Bone spicule pigmentation of the retina and Tritanomaly. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Nystagmus, Visual impairment, Optic disc pallor |
POC1B function has not been fully characterized.
Cone-rod dystrophy 20 is caused by mutations in the POC1B gene on chromosome 12.
Genetic testing for POC1B is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cone-rod dystrophy 20 has been reported in the published literature.
Phenotype severity distribution: 4 always present features, 2 common features.
No clinical trials have been registered for cone-rod dystrophy 20.
48 publications have been identified in PubMed for cone-rod dystrophy 20. Research spans Case Report / Case Series (35%), Epidemiology / Natural History (29%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 | 35% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about cone-rod dystrophy 20
Bones and joints
1 |
Bone spicule pigmentation of the retina |
14 |
29% |
Laboratory research | 6 | 13% |
Testing and diagnosis research | 4 | 8% |
New treatment approaches | 4 | 8% |
Research summaries | 2 | 4% |
Clinical study results | 1 | 2% |
Kong MD (2026). [PMID: 41557064](https://pubmed.ncbi.nlm.nih.gov/41557064/). *Doc Ophthalmol*. [Basic Science / Preclinical]
Josan AS (2026). [PMID: 41237986](https://pubmed.ncbi.nlm.nih.gov/41237986/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Romo-Aguas JC (2026). [PMID: 42022048](https://pubmed.ncbi.nlm.nih.gov/42022048/). *Ophthalmol Sci*. [Epidemiology / Natural History]
Elsayed MEAA (2026). [PMID: 41495677](https://pubmed.ncbi.nlm.nih.gov/41495677/). *BMC Ophthalmol*. [Basic Science / Preclinical]
Patil M (2026). [PMID: 41912280](https://pubmed.ncbi.nlm.nih.gov/41912280/). *Ophthalmic Genet*. [Gene Therapy / Novel Therapeutics]
Khan AO (2026). [PMID: 41166683](https://pubmed.ncbi.nlm.nih.gov/41166683/). *Retina*. [Epidemiology / Natural History]
Demirkol A (2026). [PMID: 41751276](https://pubmed.ncbi.nlm.nih.gov/41751276/). *Biomedicines*. [Diagnostic / Biomarker]
Raji S (2026). [PMID: 41481301](https://pubmed.ncbi.nlm.nih.gov/41481301/). *JAMA Ophthalmol*. [Epidemiology / Natural History]
Fabard M (2026). [PMID: 41686256](https://pubmed.ncbi.nlm.nih.gov/41686256/). *Hum Genet*. [Basic Science / Preclinical]
Parekh BJ (2026). [PMID: 41760091](https://pubmed.ncbi.nlm.nih.gov/41760091/). *Clin Exp Ophthalmol*. [Clinical Trial Publication]